Copanlisib (Aliqopa)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

History of changes in FDA indication

  • 9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies."

Also known as

  • Code name: BAY 80-6946
  • Brand name: Aliqopa

References

  1. 1.0 1.1 Copanlisib (Aliqopa) package insert
  2. Copanlisib (Aliqopa) package insert (locally hosted backup)
  3. Aliqopa manufacturer's website